drugset
Drugs / autologous CD4+ antigen-specific T-cells
last change Aug 2008 re-read 3 minutes ago

autologous CD4+ antigen-specific T-cells

Cell therapy

Developed for
cutaneous melanoma
Investigated by
Fred Hutchinson Cancer Center · National Cancer Institute (NCI)

Trials 1

today NCT00045357 · Ph 1
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00045357 Nov 2001 → Aug 2008 cutaneous melanoma Fred Hutchinson Cancer Center Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as autologous CD4+ antigen-specific T-cells “Patients receive autologous CD4+ antigen-specific T-cells IV over 30 minutes.” NCT00045357 ↗
Modality Cell therapy “cellular adoptive immunotherapy” NCT00045357 ↗
Route Intravenous “Patients receive autologous CD4+ antigen-specific T-cells IV over 30 minutes.” NCT00045357 ↗